Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study
- 1 April 2001
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 76 (4), 358-363
- https://doi.org/10.1016/s0025-6196(11)62382-3
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinencePublished by Wolters Kluwer Health ,2000
- Tolterodine, an Effective and Well Tolerated Treatment for Urge Incontinence and Other Overactive Bladder SymptomsClinical Drug Investigation, 2000
- Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinenceUrology, 1999
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999
- Economic costs of urinary incontinence in 1995Urology, 1998
- Efficacy and safety of tolterodine in patients with detrusor instability: a dose‐ranging studyBritish Journal of Urology, 1998
- Antimuscarinic Potency and Bladder Selectivity of PNU‐200577, a Major Metabolite of TolterodineBasic & Clinical Pharmacology & Toxicology, 1997
- Tolterodine-a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical dataLife Sciences, 1997
- OxybutyninDrugs & Aging, 1995
- Pulmonary effects of long-term β2-blockade in healthy subjects: Comparative study of metoprolol OROSAmerican Heart Journal, 1990